In October of 2016, the Australian Government announced the commencement of the Narcotics Drugs Amendment Act 2016 which will give patients and doctors access to safe, reliable and legal source of cannabis for medicinal use.
As a result of this change in legislation, businesses in Australia can now apply for a licence to cultivate cannabis for medicinal purposes, to manufacture medicinal cannabis products or to conduct medicinal cannabis related research under the Medicinal Cannabis Scheme.
We plan to grow the business through the manufacture of organic products and development of the MOCA brand over the next one to three years.
During this time-frame, the Company will operate on a staged approach to leverage its licences and bring a variety of medical cannabis products into our secure medical facility in New South Wales, including CBD and THC capsules, CBD oils and tinctures, sublinguals and concentrates. Our import licence enable us to wholesale our products to pharmacies, hospitals and licenced medical professionals. Our export licence enables the Company to sell products to licenced buyers around the world.
The Company will pursue its licence applications with New Zealand for importation and to establish a cultivation facility firstly for research and secondly for cultivation of marijuana for commercial sale.
We have supply agreements with licenced cannabis cultivators in the United States and in Canada that enable us to import products into Australia immediately. According to Fortune Magazine Fortune, the U.S. cannabis industry could grow to $20 billion by 2022.
Our business model
Our main source of revenue, in the first instance will be the wholesale of cannabis medications to the healthcare industry in Australia and abroad.
We will specifically target medical cannabis clinics and licenced doctors. The Company will develop educational material and brochures specifically for medical professionals to assist in prescribing MOCA cannabis products. The Company will also target emerging nations with approved medical marijuana for wholesale supply of products.
Our digital media partner, New Realm media, owns and is currently developing websites such as CannabisPrescription.com.au and rollout is anticipated late 2019 for all sites. These sites will offer the online visibility for patients seeking cannabinoid based products.
In the second instance we will generate revenue from the cultivation of raw and refined cannabis, provided our licence is approved by the New Zealand Government. Anticipated time-frame for cultivation revenue is mid to late 2020.
Our Value proposition
MOCA’s target audience, is a rapidly growing global market of people who seek wellness and relief from illness and an enhanced quality of life. Around the world, patients are seeking innovative emerging medical solutions to restore health and alleviate sickness. MOCA has developed a business case and is preparing to supply the Australian market with high quality, organic, sustainable grown cannabis medication.
Our objectives are, in the short term, to import cannabis based medication from our international partners into Australia, to supply an emerging market. Secondly, we will develop facilities to cultivate, produce and manufacture medical organic cannabis products utilizing the technology and know how of our partners. The business is orientated and based in Australia and New Zealand and has a strong focus on exporting to international markets.
Our national and international business marketing strategy is based on a strategic partnership with New Realm Media. MOCA has secured rights through a licence agreement to utilize top level domain names and websites including www.MedicinalOrganicMarijuana.com, www.CannabisPrescription.com.au and www.InvestCannabisIndustry.com as well as over 40 other top digital. MOCA stands to benefit from this distribution channel made available to a select group of suppliers.